Top Markets
#1 Derive Derive +30.44%
#2 Audiera Audiera +15.71%
#3 Geodnet Geodnet +14.67%
#4 Cross Cross +14.12%
#5 Humanity Humanity +11.02%
#6 Biconomy Biconomy +10.85%
#7 The Bitcoin Bull The Bitcoin Bull +9.78%
#8 Cap Cap +9.36%
#9 Based Based +8.40%
#10 Quack AI Quack AI +7.88%
Coin of the day
Derive Derive
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Dogwood Therapeutics, Inc. Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

DWTX
Classement en actions #35719
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to... Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Prix de l'action
$1.84
Dernière synchronisation: 2026-08-11
Capitalisation boursière
$3.51M
Changement (1 jour)
0.46%
Changement (1 an)
-62.71%
Pays
US
Échange Dogwood Therapeutics, Inc. (DWTX)

Catégorie

Healthcare
Bénéfices pour Dogwood Therapeutics, Inc. (DWTX)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Dogwood Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Dogwood Therapeutics, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE